Latest filings (excl ownership)
EFFECT
Notice of effectiveness
3 May 24
D
$1.28 mm in options / securities to be acquired, sold $1.28 mm, 3 investors
25 Apr 24
S-1
IPO registration
24 Apr 24
8-K
Other Events
19 Apr 24
424B5
Prospectus supplement for primary offering
19 Apr 24
8-K
Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the- Market Under Nasdaq Rules
19 Apr 24
424B5
Prospectus supplement for primary offering
19 Apr 24
8-K
Other Events
18 Apr 24
8-K
Bio-Path Holdings Expands Global Patent Portfolio
15 Apr 24
D
$317.93 k in options / securities to be acquired, sold $317.93 k, 1 investor
5 Apr 24
8-K
Entry into a Material Definitive Agreement
4 Apr 24
424B5
Prospectus supplement for primary offering
4 Apr 24
8-K
Bio-Path Holdings Provides 2024 Clinical and Operational Update
2 Apr 24
8-K
Other Events
27 Mar 24
424B5
Prospectus supplement for primary offering
27 Mar 24
8-K
Entry into a Material Definitive Agreement
26 Mar 24
RW
Registration withdrawal request
25 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
13 Mar 24
S-1/A
IPO registration (amended)
13 Mar 24
8-K
Other Events
11 Mar 24
S-1
IPO registration
8 Mar 24
8-K
Bio-path Holdings Reports Full Year 2023 Financial Results
8 Mar 24
10-K
2023 FY
Annual report
7 Mar 24
RW
Registration withdrawal request
29 Feb 24
8-K
Bio-Path Holdings Announces 1-for-20 Reverse Stock Split
23 Feb 24
8-K
Submission of Matters to a Vote of Security Holders
2 Feb 24
DEFA14A
Additional proxy soliciting materials
24 Jan 24
8-K
Submission of Matters to a Vote of Security Holders
23 Jan 24
S-1/A
IPO registration (amended)
23 Jan 24
DEFA14A
Additional proxy soliciting materials
17 Jan 24
8-K
Targeting Bcl-2 Protein Offers Potential Treatment for Patients Who Have Failed or Relapsed from Venetoclax-Based Frontline Therapy
10 Jan 24
DEF 14A
Definitive proxy
4 Jan 24
PRE 14A
Preliminary proxy
22 Dec 23
S-1
IPO registration
22 Dec 23
8-K
Submission of Matters to a Vote of Security Holders
15 Dec 23
8-K
Bio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia
14 Dec 23
DEFA14A
Additional proxy soliciting materials
8 Dec 23
8-K
Amendments to Articles of Incorporation or Bylaws
8 Dec 23
8-K
Bio-path Holdings Reports Third Quarter 2023 Financial Results
15 Nov 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
Latest ownership filings
SC 13G
INTRACOASTAL CAPITAL, LLC
3 Apr 24
SC 13G
Hudson Bay Capital Management LP
2 Feb 24
4
Heath Cleaver
4 May 23
4
Paul Aubert
4 May 23
4
Aline Sherwood
4 May 23
4
DOUGLAS P MORRIS
4 May 23
4
Peter Henry Nielsen
4 May 23
4
Aline Sherwood
8 Apr 22
3
Aline Sherwood
8 Apr 22
4
DOUGLAS P MORRIS
30 Mar 22
4
Heath Cleaver
30 Mar 22
4
Paul Aubert
30 Mar 22
4
Peter Henry Nielsen
25 Mar 22
4
Heath Cleaver
31 Mar 21
4
DOUGLAS P MORRIS
31 Mar 21
4
Peter Henry Nielsen
31 Mar 21
4
Tamaro Martina Molsbergen
31 Mar 21
4
Paul Aubert
31 Mar 21
4
Peter Henry Nielsen
18 Jun 20
4
DOUGLAS P MORRIS
31 Mar 20
4
Heath Cleaver
31 Mar 20
4
Paul Aubert
31 Mar 20
4
Tamaro Martina Molsbergen
31 Mar 20
4
Peter Henry Nielsen
20 Mar 20
SC 13G/A
Bio-path Holdings Inc
14 Feb 20
SC 13G/A
Bio-path Holdings Inc
14 Feb 20
SC 13G/A
Bio-path Holdings Inc
10 Feb 20
SC 13G/A
Bio-path Holdings Inc
15 Jan 20
SC 13G/A
Bio-path Holdings Inc
6 Jan 20
SC 13G
Bio-path Holdings Inc
2 Dec 19
SC 13G
Bio-path Holdings Inc
2 Dec 19
SC 13G
Bio-path Holdings Inc
27 Nov 19
3
Tamaro Martina Molsbergen
22 Oct 19
4
MARK P COLONNESE
1 Apr 19
4
Paul Aubert
1 Apr 19
4
Peter Henry Nielsen
1 Apr 19
4
DOUGLAS P MORRIS
1 Apr 19
4
Heath Cleaver
1 Apr 19
SC 13G
Bio-path Holdings Inc
15 Mar 19
SC 13G
Bio-path Holdings Inc
14 Mar 19